Related Experiment Video
Updated: Jul 29, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Raloxifene: a new choice for treating and preventing osteoporosis
A A Licata1, A V Ciaccia, M Wong
1Department of Endocrinology, Cleveland Clinic, OH 44195, USA. licataa@ccf.org
Selective estrogen receptor modulators (SERMs) offer new therapeutic options for postmenopausal women. This review covers SERM mechanisms and clinical data on raloxifene for osteoporosis treatment and prevention.
Area of Science:
- Pharmacology
- Endocrinology
- Women's Health
Background:
- Postmenopausal health challenges require novel therapeutic strategies.
- Selective estrogen receptor modulators (SERMs) represent a new drug class.
- Estrogen signaling plays a critical role in postmenopausal health.
Purpose of the Study:
- To review the mechanism of action of SERMs.
- To present clinical findings on raloxifene.
- To highlight raloxifene's utility in managing postmenopausal osteoporosis.
Main Methods:
- Literature review of SERM pharmacology.
- Analysis of clinical trial data for raloxifene.
- Synthesis of evidence on osteoporosis treatment and prevention.
Main Results:
- SERMs exhibit tissue-specific estrogenic and anti-estrogenic effects.
- Raloxifene has demonstrated efficacy in reducing vertebral fracture risk.
- Raloxifene is approved for osteoporosis treatment and prevention in postmenopausal women.
Conclusions:
- SERMs, exemplified by raloxifene, provide a valuable therapeutic avenue.
- Raloxifene effectively addresses osteoporosis in postmenopausal women.
- Further research into SERM applications continues to evolve.
Related Concept Videos
Bone Remodeling
Osteoclasts in Bone Remodeling
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Antidepressant Drugs: MAOIs and Other Agents
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

